Despite running a pair of its older drugs through coronavirus trials, British drugmaker AstraZeneca has been noticeably absent in the pursuit for a vaccine. Not anymore. The company has inked a new deal with the University of Oxford that could help it hopscotch right into the lead.AstraZeneca snared global manufacturing and distribution rights to Oxford's adenovirus-based COVID-19 shot, which leapfrogged into front-runner status when it began human trials last week. FiercePharma
Thursday, April 30, 2020
AstraZeneca vaults ahead in COVID-19 vaccine race with 'landmark' Oxford deal
Despite running a pair of its older drugs through coronavirus trials, British drugmaker AstraZeneca has been noticeably absent in the pursuit for a vaccine. Not anymore. The company has inked a new deal with the University of Oxford that could help it hopscotch right into the lead.AstraZeneca snared global manufacturing and distribution rights to Oxford's adenovirus-based COVID-19 shot, which leapfrogged into front-runner status when it began human trials last week. FiercePharma
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment